伊贝沙坦治疗轻中度高血压的临床疗效及安全性观察.docVIP

伊贝沙坦治疗轻中度高血压的临床疗效及安全性观察 　　作者：田玉军　钟 进 　作者单位： 416000 湖南吉首，吉首市人民医院内科 　　【摘要】 目的 评价伊贝沙坦治疗高血压的有效性和安全性。方法 采用随机、对照法观察伊贝沙坦治疗轻、中度原发性高血压8周的疗效。46例原发性轻中度高血压的患者随机分为两组，分别服用伊贝沙坦(150mg，1次/d)或卡托普利(25mg，2次/d)，治疗8周。治疗前及8周末进行各项实验室检查，每2周随访1次，记录受试者的血压、心率、不良反应。结果 两组治疗前后收缩压与舒张压的下降均差异有显著性，伊贝沙坦组有效率为89%，卡托普利组有效率为80%，组间比较差异无显著性。两组治疗前后心率及各项实验室检测结果无显著性变化。不良反应轻微，均能耐受至试验结束。结论 伊贝沙坦是新型的ARB类药物，在治疗轻、中度高血压的过程中安全有效，不良反应轻微，患者能很好耐受。 　　【关键词】 伊贝沙坦;原发性高血压;临床疗效;安全性 　　Observation of clinical efficacy and safty of mild and moderate essential hypertension treated with irbesartan 　　TIAN Yu-jun,ZHONG Jin. Peoples Hospital of Jishou,Hunan 416000，China 　　【Abstract】 Objective To evaluate the efficacy and safety of essential hypertension with irbesartan.Methods A randomized,double blind study was carried out on 46 patients with stage 1 and 2 essential hypertension.Patients were divided randomly into two groups and given either irbesartan (irbesartan group) or captopril (captopril group ) for 8 weeks.Results The average reduction in blood pressure readings for the two treatment groups were 89% and 80% respectively.No significant differences were found between two groups (P0.05).SBP and DBP were decreased significantly on the second week following treatment,and reached their peaks on the fourth week following treatment,and this effect was sustained until the end of the study.No changes of HR were found throughout the study.No significant changes were found for routine blood examination,liver and renal functions,or electrocardiography after treatment.No adverse effects were observed during the study.Conclusion Irbesartan is a new type of ARB,which as well as captopril has good hypertensive effects.It can be tolerated by the patients. 　　【Key words】 irbesartan;essential hypertension;clinical efficacy;safety 　　伊贝沙坦(irbsartan)是一种高选择性的血管紧张素Ⅱ(AngⅡ)受体拮抗剂,可选择性地作用于AngⅡ受体的AT1亚型1～3，抑制AngⅡ升压效应而起到降压作用。血管紧张素转换酶抑制剂也作用于肾素-血管紧张素系统,但作用机制不同。本研究采用随机、开放、平行对照治疗研究,比较伊贝沙坦和卡托普利的降压效应与安全性。 　　1 资料与方法 　　1.1 一般资料 按